Why We Need to Search for the Truth in Cancer Cure Stories – Ovarian Cancer Help Part 3

Last week on Navigating the Cancer Maze on Voice America Health and Wellness Channel, I mentioned a immune treatment that is being acclaimed as a value add therapy for many cancer patients – in particular, those dealing with ovarian Cancer…

 Last week on Navigating the Cancer Maze on Voice America Health and Wellness Channel, I mentioned a immune treatment that is being acclaimed as a value add therapy for many cancer patients – in particular, those dealing with ovarian Cancer…

The links and information follows:DENVAXTM – DENDRITIC CELL THERAPY – Customized Cell-based Cancer Immunotherapy INSTITUTE OF CELLULAR THERAPIES ( source )

ovarian cancer
Ovarian Cancer – Dendritic cell vaccine shows promise

Ovarian cancer: A 58 yr old lady was diagnosed of cancer ovary in June 2004. Her CA 125 antigen marker was positive and in the range of 10,000 units. She was operated upon and given six cycles of chemotherapy. She recovered from her disease and her marker was also within normal range.  After one year, the CA 125 began rising and she presented to us with an increased titre of 400 units. There were signs of recurrence, and she opted for DC (DENVAX) therapy in June 2005. She has completed three years of receiving DENVAX. She is free of disease, proven both clinically and by radiological examinations. Her CA 125 marker is also stable for the last three years.

http://www.dendriticcellresearch.com/success_stories
http://www.dendriticcellresearch.com/publications

CUSTOMIZED DENDRITIC CELL IMMUNOTHERAPY IN CANCER

Another treatment greatly assisting Ovarian cancer patients is used by Hallwang Private Oncology Clinic in Germany. Removab – a trifunctional antibody has been used at the Clinic for many years Click Here for information


Last week I also discussed
a new book by controversial American Cancer Physician Dr David Agus. His latest book A Short Guide to a Long Life by David B. Agus, MD, is published by Simon & Schuster ($24.99) and available on Amazon.

In his #1 New York Times bestselling book, The End of Illness, Dr. David B. Agus shared what he has learned from his work as a pioneering cancer doctor and researcher, revealing the innovative steps he takes to prolong the lives of not only cancer patients but all those hoping to enjoy a vigorous, lengthy life.

Now Dr. Agus has turned his analysis into a practical and concise illus­trated handbook for everyday living. He believes optimal health begins with our daily habits.

In A Short Guide to a Long Life, David Agus espouses the idea that prolonged good health starts with lots of smallish changes today. Much of the advice – don’t skip breakfast; avoid sunburn – will be familiar. He notes that Hippocrates made many of the same observations – “Walking is man’s best friend”; “Let food be thy medicine and medicine be thy food” – in the 4th century BC. Yet the truth is that few of us have so far incorporated them into our lives.

Some of Agus’s rules are cute: for instance, “Smile – the act itself will trigger the release of pain-killing, brain-happy endorphins and serotonin.” Others seem quirky – he’s adamantly against high heels: they cause inflammation, which can raise your lifetime risk of heart attack, strokes and cancer, he says.
A few of his dictums will give pause for uncomfortable thought. Rule 56 says to avoid airport backscatter X-ray scanners. Until science can prove they’re safe, Agus says, “I’ll be requesting the manual pat-down massage when I go through airports. You should, too.”
He debunks fads: rule 60 is “No Juicing”. “Does the body really like consuming 10 carrots all at once? Or a pound of radishes? I think not.” Or how about “Eat real food”. That means avoiding anything in a packet. It doesn’t matter if it announces itself to be good for you somehow by being, say, “cholesterol free” or “antioxidant rich”. “If they have to tell you why you should be eating it, you shouldn’t be eating it.”
In the book, Agus’s voice is calm and reassuring. In person, it’s more urgent. At one point he asks me if I’ve had a flu shot this year. I haven’t. “You should get it now,” he says. “If you get the flu, in a decade from now your chance of cancer or heart disease is elevated … So go and get that flu shot if you want to play with those grandkids. It’s a sore arm.”
Like most cancer doctors he sees the advanced disease; what can’t be reversed.   He wants to instil a new way of thinking about cancer. It’s not something that visits us from outside, he says. We don’t “get” cancer. Rather, we need to stop our bodies from “cancering”. Cancer is a verb, not a noun.
Some rules for living longer – A Short Guide to a Long Life by David B. Agus, MD

Caffeine, especially from traditional sources, may have protective, anti-cancer properties. But moderation is key.
Smiling triggers the release of pain-killing, brain-happy endorphins and serotonin.
Uncomfortable shoes cause inflammation that can have an impact on your entire system … Inflammation has been linked to heart disease, Alzheimer’s, cancer, autoimmune diseases and diabetes.
– Track your movement during the day with an accelerometer, and develop a daily personal activity target. Being sedentary is about as bad for you as smoking.
Cleanliness counts. Wash your hands regularly, especially after exposure to germy things such as bathrooms.
To reap the benefits of exercise, including all those biochemical reactions that lower your risk of illness, aim to break a sweat and get your heart pumping fast for a minimum of 15 minutes a day.
Moderate alcohol intake, especially from red wine, can reduce one’s risk of heart disease. This benefit does have a caveat: drinking can potentially increase one’s risk for breast cancer, and drinking too much is far worse for your heart than being a teetotaller. Agus has a glass of red a day.
Cold-water fish, such as salmon, sardines, tuna, trout, anchovies, herring, halibut, cod, black cod, mackerel and mahi-mahi are excellent sources of high-quality protein, healthy fats and naturally occurring vitamins and minerals.
A daily low-dose aspirin (75mg) has been shown to reduce the risk of developing common malignant cancers in the lungs, colon and prostate by 46 per cent. So if you’re basking in the glory of middle age, this is something to discuss with your doctor. It’s the cheapest fountain of youth around and requires no prescription.  Read the article about Dr David Agus in the Australian Good Weekend Magazine

 Voice America Grace Gawler

 

Groundbreaking Cancer Immunotherapy Grace Gawler interviews Dr Horst Lindhoffer Munich

On today’s edition of Navigating the Cancer Maze, Grace Gawler interviews Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer immunotherapy treatment breakthroughs in many years. Visit germancancertreatments.com for more information.

On Navigating the Cancer Maze – Cancer Immunotherapy – Ground-breaking treatment in Cancer Medicine Grace Gawler -August 2, 2013

 “Destroying cancer stem cells means fighting cancer at its roots”, says Horst Lindhofer, CEO of TRION Pharma. “Catumaxomab’s efficacy against this particularly aggressive and resistant population of cancer cells further supports its therapeutic potential for the treatment of EpCAM-positive carcinomas.”

On today’s edition of Navigating the Cancer Maze, I interview Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer treatment breakthroughs in many years. We know that The human immune system is usually quite effective at identifying and eliminating abnormal cells.

dr horst lindhofer
Dr Horst Lindhofer

 Cancer cells, however, can form tumors and spread throughout the body. Although chaotic in their behavior, cancer cells operate with high level intelligence to escape detection by our immune system’s control mechanisms. Often misunderstood, this is a fundamental principle in understanding how cancer cells behave and how immune recognition can be assisted. The new breakthrough cancer treatments capitalize on that information. It has been a long-standing vision of physicians and scientists to develop a treatment that can put the immune system back on track. TRION has achieved the goal with its trifunctional Triomab® antibodies. Listen to learn more or contact grace@germancancertreatments.com for further details.

Listen to this interview at:
http://www.voiceamerica.com/episode/72038/cancer-immunotherapy-ground-breaking-treatment-in-cancer-medicine
Catumaxomab (Removab®) is presently the only approved therapeutic antibody targeting EpCAM, a surface antigen that is widely expressed in the most frequent forms of human cancer. On April 20th this year, Removab® received EU approval for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Removab® is the first product world-wide to receive a regulatory approval for this indication. With its trifunctional mode of action, Removab® represents a new generation of antibodies using the body’s own immune system to help fight the tumor cells.

For more information visit www.germancancertreatments.com Enquiries: To discover more about Horst Lindhoffer’s work with Trifunctional antibodies  – please email grace@germancancertreatments.com

EpCAM: EpCAM or epithelial cell adhesion molecule is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas, such as breast, lung, colorectal, gastric, prostate and ovarian cancer. Catumaxomab (Removab®) is the only approved anti-EpCAM antibody available.

Triomab®: Trifunctional antibodies : Triomab® antibodies bind to cancer-specific surface antigens and recruit both T cells as well as accessory cells, such as macrophages, dendritic cells and natural killer cells, to the tumor site. As a result, they provide for a new quality of cancer cell killing, activating both arms of the immune system – the adaptive one with cytotoxic T cells as effectors and the innate one including accessory effector cells.

dendritic cell image
dendritic cell image

Triomab® antibodies are therefore very effective in destroying cancer cells and show a therapeutic effect at very low doses. Triomab® antibodies are a development of TRION Pharma GmbH Catumaxomab was invented by TRION Pharma and has been developed with Fresenius Biotech.

Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer: On June 06, 2011 Munich, Germany TRION Pharma GmbH released and announced new information – the results from two different studies demonstrating catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination.  Continue reading “Groundbreaking Cancer Immunotherapy Grace Gawler interviews Dr Horst Lindhoffer Munich”